EPISODE · Apr 23, 2026 · 15 MIN
$100 Billion GLP-1 Weight Loss Problem No One is Talking About
from the Joshua Schall Audio Experience · host Joshua Schall
The "Ozempic Era" winner won't just be the company that ships the most pens...it’ll be the one that provides the most holistic support for the patient's new metabolic reality. For years, Hims & Hers has been the gold standard for "full-stack" digital health, successfully turning stigmatized medical treatments into lifestyle rituals. But as they dive deeper into the GLP-1 market, the rules of the game have changed. As of March 2026, they’ve shifted away from "compounded" medications toward FDA-approved branded drugs like Wegovy. This move avoids legal and regulatory risks, but it creates a massive problem: They can no longer "bundle" supplements into the pill. Although accessibility of GLP-1 medications isn’t the true challenge of obesity care any longer. Alternatively, the GLP-1 revolution faces a real problem with retention. Data shows that 62% of GLP-1 users quit within six months. Why? Side effects like "Ozempic Face" (loss of skin elasticity), significant muscle mass loss (up to 40% of weight lost), and debilitating GI issues. So, the future of Hims & Hers isn't just shipping injection pens; it’s becoming a comprehensive metabolic health platform. And this likely involves a "dual-track" subscription model. On one track, the patient receives the branded GLP-1 pharmaceutical. On the second track, they also receive a customized monthly "metabolic health support kit." And I’d expect these support kits to include a customized monthly stack focused on Muscle Preservation (Protein, HMB, and Creatine), GI Defense (Fiber, Prebiotics, and Electrolytes), and Cosmetic Repair (Nutricosmetics). But to win the long game, Hims & Hers may need to look toward precision nutrition. Whether through AI-driven personalized supplements (like Tailored Script from TSI Group) or 3D-printed nutrient gummies (like Nourish3d), the goal is clear...every aspect of the "hard goods" strategy must move from a reactive "one-size-fits-all" approach to a proactive, personalized metabolic health care model.
What this episode covers
The "Ozempic Era" winner won't just be the company that ships the most pens...it’ll be the one that provides the most holistic support for the patient's new metabolic reality. For years, Hims & Hers has been the gold standard for "full-stack" digital health, successfully turning stigmatized medical treatments into lifestyle rituals. But as they dive deeper into the GLP-1 market, the rules of the game have changed. As of March 2026, they’ve shifted away from "compounded" medications toward FDA-approved branded drugs like Wegovy. This move avoids legal and regulatory risks, but it creates a massive problem: They can no longer "bundle" supplements into the pill. Although accessibility of GLP-1 medications isn’t the true challenge of obesity care any longer. Alternatively, the GLP-1 revolution faces a real problem with retention. Data shows that 62% of GLP-1 users quit within six months. Why? Side effects like "Ozempic Face" (loss of skin elasticity), significant muscle mass loss (up to 40% of weight lost), and debilitating GI issues. So, the future of Hims & Hers isn't just shipping injection pens; it’s becoming a comprehensive metabolic health platform. And this likely involves a "dual-track" subscription model. On one track, the patient receives the branded GLP-1 pharmaceutical. On the second track, they also receive a customized monthly "metabolic health support kit." And I’d expect these support kits to include a customized monthly stack focused on Muscle Preservation (Protein, HMB, and Creatine), GI Defense (Fiber, Prebiotics, and Electrolytes), and Cosmetic Repair (Nutricosmetics). But to win the long game, Hims & Hers may need to look toward precision nutrition. Whether through AI-driven personalized supplements (like Tailored Script from TSI Group) or 3D-printed nutrient gummies (like Nourish3d), the goal is clear...every aspect of the "hard goods" strategy must move from a reactive "one-size-fits-all" approach to a proactive, personalized metabolic health care model.
NOW PLAYING
$100 Billion GLP-1 Weight Loss Problem No One is Talking About
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.